二肽基肽酶-4抑制剂心血管保护作用的研究进展
Progress in the investigation of cardiovascular protective effects of DPP-4 inhibitors
二肽基肽酶-4(DPP-4)抑制剂是一种新型的2型糖尿病治疗药物,通过抑制DPP-4,升高包括胰升糖素样肽-1(GLP-1)在内的多种内源性肠促胰岛素,产生降糖作用.除升高GLP-1外,DPP-4还能广泛裂解炎症、免疫和血管功能调节中涉及的多种细胞因子、趋化因子和神经肽.已经证实GLP-1具有心血管系统的保护作用,由于上述非靶机制的存在,DPP-4抑制剂还具有独立于GLP-1之外的心血管保护作用,其中对内皮祖细胞、炎症过程、缺血反应和血脂的调节是其主要作用靶点.
更多Dipeptydil-peptidase-4 (DPP-4) inhibitors are designed as oral anti-hyperglycemic drugs for the treatment of type 2 diabetes owing to their effects on the incretin system through sparing incretin hormones including glucagon-like peptide-1 (GLP-1) from rapid degradation by DPP-4.It has been shown that GLP-1 signaling may exert beneficial effects on cardiovascular system.In addition to GLP-1,DPP-4 physiologically cleaves cytokines,chemokines,and neuropeptides involved in inflammation,immunity,and vascular function.It means that DPP-4 inhibitors hold promise for cardiovascular protection independent of GLP-1.And its modulation of endothelial progenitor cells,infiammatory pathway,ischemic response,and lipid metabolism emerges as the major cardiovascular target of DPP-4 inhibitors.
More- 浏览:369
- 被引:9
- 下载:493
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文